Effect of CHF6001, a novel inhaled phosphodiesterase-4 inhibitor (PDE4i) on markers of inflammation in COPD patients

被引：0

作者：

Singh, Dave ^{[1
]}

Govoni, Mirco ^{[2
]}

Bassi, Michele ^{[2
]}

Beeh, Kai Michael ^{[3
]}

Colgan, Brendan ^{[4
]}

Kornmann, Oliver ^{[5
]}

Laeker, Brian ^{[6
]}

Watz, Henrik ^{[7
]}

Lucci, Germano ^{[2
]}

Geraci, Silvia ^{[2
]}

Rocco, Emanuele Calabro ^{[2
]}

Emirova, Aida ^{[8
]}

Nandeuil, Marie Anna ^{[8
]}

机构：

[1] Univ Manchester, Med Evaluat Unit, Manchester, Lancs, England

[2] Chiesi Farmaceut SpA, Global Clin Dev, Parma, Italy

[3] Insaf Resp Res Inst, Wesbaden, Germany

[4] Celerion, Belfast, Antrim, North Ireland

[5] IKF Pneumol Frankfurt, Clin Res Ctr Resp Dis, Frankfurt, Germany

[6] Heart Lung Ctr, London, England

[7] Lung Clin, Pulm Res Inst, Grosshansdorf, Germany

[8] Chiesi SAS, Global Clin Dev, Bois Colombes, France

来源：

关键词：

Biomarkers; COPD; -; management; Anti-inflammatory;

D O I：

10.1183/13993003.congress-2019.PA2044

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

PA2044

引用

页数：2